Background {#Sec1}
==========

Breast cancer is a heterogeneous group of pathologic entities with different risk of recurrence and therapy response \[[@CR1]\]. In order to improve breast cancer diagnosis and treatment decision, it is necessary to gain a better understanding of the metastatic pathways and etiology.

Annexin A1 (ANXA1) protein binds the cellular membrane phospholipids in a Ca^2+^ regulated manner and can be phosphorylated on several residues both on the N-terminal functional domain and on the C-terminus core \[[@CR2]\] by different proteins, such as the epidermal growth factor receptor (EGFR) \[[@CR3]\], insulin receptor (IR) \[[@CR4]\], TRPM7 channel kinase 1 (ChaK1) \[[@CR5]\], protein kinase C (PKC) and protein kinase A (PKA) \[[@CR6]\]. ANXA1 has been found in several tissues and regulates physiological mechanisms such as hormone secretion \[[@CR7]\], EGFR degradation \[[@CR8]\], membrane transport \[[@CR9]\], apoptosis \[[@CR10]\] and cell differentiation \[[@CR11]\]. As a glucocorticoid-induced molecule, ANXA1 plays an important role in the inflammatory response \[[@CR12]\].

ANXA1 expression is related with the carcinogenesis process \[[@CR13]--[@CR15]\] and with metastasis formation in many tumors \[[@CR16]--[@CR18]\], including breast tumors \[[@CR19]--[@CR23]\], where we and others have shown that ANXA1 overexpression is associated with high pathological differentiation grade, lack of hormone receptor expression and a basal-like phenotype \[[@CR20], [@CR24], [@CR25]\]. Patients with *BRCA1* or *BRCA2* (*BRCA1/2*) germline mutations often present tumors with these characteristics, but until now there are no data in the literature implicating a link between high ANXA1 expression and familial breast cancer. The main focus of this study was to analyze the relationship between high ANXA1 tumor expression with *BRCA1/2* germline carriership and survival in breast cancer patients, including those with specific tumor subtypes, using a large dataset of pooled breast cancer series. These analyses allow us to explore the potential of ANXA1 as a marker for breast cancer outcome prediction and treatment response.

Methods {#Sec2}
=======

Study populations {#Sec3}
-----------------

The international Breast Cancer Association Consortium (BCAC) comprises a large number of studies investigating the role of common germline genetic variation in breast cancer susceptibility \[[@CR26]\]. Nine studies from Europe, North America, New Zealand and Australia contributed with 8,182 cases to this ANXA1 study (Additional file [1](#MOESM1){ref-type="media"}: Table S1). All studies were approved by the relevant ethics committees and informed consent was obtained from all participants (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Clinical-pathological information and follow-up data were collected by each study individually through medical records, cancer registries and cause of death registries. Data were pooled in the BCAC database according to a data dictionary, and centrally checked for accuracy and consistency. Data included were: age at diagnosis; behavior (*in situ* or invasive); morphology (ductal, lobular and others); tumor size (≤2 cm, \>2 and ≤5 cm, or \>5 cm); differentiation grade (1, 2 or 3); lymph node status (negative or positive); and breast cancer treatment (radiotherapy, hormonal therapy and chemotherapy). The most common source of data for ER, PR and HER2 status was from medical records, followed by immunohistochemistry (IHC) performed on tumor tissue microarrays (TMAs) or whole section tumor slides. The subtypes were defined as follows: luminal 1 (ER+ and/or PR+ and HER2-); luminal 2 (ER+ and/or PR+ and HER2+); HER2-like (ER-, PR- and HER2+); and triple negative (ER-, PR- and HER2-). Data on CK5/6 and EGFR tumor status were derived from IHC performed on TMAs or whole sections detailed previously \[[@CR27]\]. The p53 staining data (received only from one breast cancer study) and the *BRCA1* and *BRCA2* status mutation of the BCAC patients were obtained as described previously \[[@CR28], [@CR29]\]. A specific cohort of 132 *BRCA1/2* mutated (BRCA1\|2), familial breast cancer patients (a minimum of three first- or second-degree relatives affected with breast and/or ovarian cancer in a family) were included from the Helsinki University Central Hospital (HUCH) in southern Finland as described previously \[[@CR30]\]. In addition, within the BCAC there were a few cases from some studies known to be *BRCA1/2* mutated and we excluded these for the analyses comparing BCAC with BRCA1\|2 tumors.

ANXA1 staining {#Sec4}
--------------

Ninety TMA slides from 8,705 patients were received for ANXA1 staining (including 1 to 6 tumor cores per patient). The ANXA1 staining was performed at the Core Facility Molecular Pathology and Biobanking (CFMPB) at the NKI-AVL on a BenchMark ULTRA autostainer (Ventana Medical Systems, Tucson, AZ, USA). Briefly, paraffin sections were heated at 75 °C for 28 min and deparaffinized in the instrument with EZ Prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1; Ventana Medical Systems) for 64 min at 95 °C. ANXA1 was detected by incubating sections with antibody clone 29/Annexin I (610066; BD Transduction Laboratories, Franklin Lakes, NJ, USA), 1/1500 dilution for 1 h. Specific reactions were detected using ultraView Universal DAB Detection Kit (Ventana Medical Systems) and slides were counterstained with hematoxylin.

The ANXA1 expression in tumor cells was scored only if the spot was evaluable, subjectively defined as approximately more than 30 % of tumor cells present in the spot. ANXA1 is also expressed in stromal cells but this was not included in the evaluation. Three variables were evaluated: intensity of the staining (negative, weak, moderate or strong); cellular location of the staining (cytoplasm and nucleus or only in cytoplasm); and the percentage of stained cells (0 % to 100 %). Scores were categorized as: 0, no expression; 1+, 10 % to 30 % stained; 2+, 40 % to 70 %; and 3+, 80 % or more cells stained (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). The intensity of the staining and the cellular location scores did not contribute to the discernment of different groups by ANXA1 stains and therefore were not further used in the analysis (Additional file [3](#MOESM3){ref-type="media"}: Figures S2A and S2B).

Evaluation of ANXA1 expression levels were performed by MdG with consultation of three pathologists (JW, JS and VTS). The concordance was around 81.7 % and 92.4 % among all of them, considering 0 or 1+ as negative and 2+ or 3+ as positive, with a kappa value of 0.86, considering positive versus negative cases between MdG and JW. A subset of 452 patients in the previously published ABCS study were rescored for this study \[[@CR24]\].

Around 20 % (n = 2,124) of the included patients enrolled in TMA constructions could not be scored due to technical problems (no sample or less than 30 % of tumor cells in the spot), but the clinical-pathological variable distributions did not differ between patients with or without ANXA1 scores (Additional file [4](#MOESM4){ref-type="media"}: Table S2). For analyses, we clustered 0 and 1+ groups based on previous experience \[[@CR24]\]. Of note, overall survival (OS) and breast cancer-specific survival (BCSS) did not differ between the 0 and 1+ groups nor between the 2+ and 3+ groups (Additional file [3](#MOESM3){ref-type="media"}: Figures S2C and S2D).

Statistical analyses {#Sec5}
--------------------

In total, we included 6,177 patients for descriptive analysis. For association and survival analysis, the *in situ* breast cancer cases were excluded (n = 204). Patients diagnosed with distant metastases at diagnosis of the primary tumor (n = 31) and those who received chemotherapy before the surgery (n = 84) were also excluded (Additional file [5](#MOESM5){ref-type="media"}: Figure S3).

In the case of significant associations between ANXA1 expression and a histopathological variable as evaluated by the Chi-square test, the odds ratios (OR) and their respective 95 % confidence intervals (95 % CI) adjusted for independent clinical variables (OR~adj~) were assessed using logistic regression models. The ANXA1 expression was tested for linear-by-linear associations to calculate trend significances (P~trend~) between tumor subtypes in Fig. [1](#Fig1){ref-type="fig"}. The statistical association analyses were conducted using SPSS 20 (SPSS Inc., Chicago, IL, USA).Fig. 1ANXA1 expression profile. Percentage of patients with ANXA1 positive tumors according to breast cancer subtypes comparing BCAC (excluding 37 patients with *BRCA1* or *BRCA2* mutations) versus *BRCA1/2* mutation carriers. For the subtype analysis, patients with missing information for ER, PR and/or HER2 were excluded (393 in BCAC and 36 in *BRCA1/2* mutation carriers). Luminal 1 subtype was defined as ER+ and/or PR+ and HER2-, and triple negative (TN) was defined as ER-, PR- and HER2-. Numbers of HER2+ were too small in the *BRCA1/2* mutation carriers to make a comparison. ANXA1: Annexin A1; BCAC: Breast Cancer Association Consortium; TN: Triple negative

Survival time was calculated from date of diagnosis to date of death/censoring. In order to allow for prevalent cases, time at risk was calculated from date of study entry to date of death/censoring. This generates an unbiased estimate of the hazard ratio (HR) provided the Cox proportional hazards assumption holds \[[@CR31]\]. End of follow-up was defined as the date of (breast cancer) death, last follow-up or 10 years, whichever came first. Distant metastasis-free survival (DMFS) analysis was performed as well, with time censored at 5 years. HRs were estimated using Cox regression models, stratified by BCAC studies. Multivariate Cox models were fitted including the variables associated with breast cancer prognosis: age at diagnosis as continuous variable; tumor grade (1, 2 or 3); tumor size (≤2 cm, \>2 cm and ≤5 cm, or \>5 cm); lymph node status (negative versus positive); ER/PR status (ER and PR negative versus ER or PR positive); and HER2 receptors status (negative versus positive) as categorical covariates. The analyses were performed as a complete case analysis and a secondary analysis was performed including the missing values in the model. ER/PR status was included as a time-varying covariate because of violation of the proportional hazards assumption using the Schoenfeld residuals test in the multivariable model (*P* \<0.0001). Adjustment for chemotherapy and/or hormonal therapy did not significantly change the results and these were not included in the final models. All *P* values reported are from two-sided tests and the threshold for significance was set at *P* = 0.05. The survival analyses were performed using STATA version 11.0 (StataCorp, TX, USA).

Results {#Sec6}
=======

Analyses included 5,752 patients from BCAC cohorts, including cases not known to be *BRCA1/2* carriers, and 107 breast cancer patients from one study of familial breast cancer patients with *BRCA1/2* mutations (Table [1](#Tab1){ref-type="table"}; Additional file [4](#MOESM4){ref-type="media"}: Table S2; Additional file [5](#MOESM5){ref-type="media"}: Figure S3).Table 1ANXA1 expression and clinical variablesBCAC patientsBRCA1\|2 mutation carriersANXA1 negativeANXA1 positiveANXA1 negativeANXA1 positiven%n%*P* value^a^n%n%*P* value^b^*P* value^c^5,04087.671212.45551.45248.6\<0.0001Age of diagnosis\<0.00010.22530.0401 \<50 years old2,46285.641314.43447.23852.8 ≥50 years old2,57889.629910.42160.01440.0 Missing0000*BRCA* status0.00260.0583 Non-carrier85883.616816.4  *BRCA1*1161.1738.92542.43457.6  *BRCA2*1473.7526.33062.51837.5 Missing3,81243000Menopausal status0.0330 Pre-1,55686.225013.8 Post-2,25888.329811.7 Missing1,226164Morphology\<0.00010.59460.0235 Ductal3,55886.256813.83350.83249.2 Lobular71094.3435.71161.1738.9 Missing7721011113Grade\<0.00010.00400.1460 11,12995.0595.0777.8222.2 22,24692.81737.22666.71333.3 31,30675.243124.81935.83464.2 Missing3594933Tumor size\<0.00010.99100.7780 ≤2 cm2,80988.835411.23151.72948.3 \>2 cm and ≤5 cm1,61086.525213.51952.81747.2 \>5 cm10979.92921.0250.0250 Missing5127734Node status0.2725 Negative2,66987.139512.93147.03553.00.30440.1790 Positive1,95588.126311.92259.51540.5 Missing4165422ER status\<0.0001 Negative97767.846532.21328.33371.7\<0.00010.7373 Positive3,79695.02005.03675.01225.0 Missing2674767PR status\<0.0001 Negative1,43575.945524.12035.13764.9\<0.00010.1670Positive3,15994.81755.22777.1822.9 Missing4468287HER2 status0.1328 Negative3,48488.744211.32548.12751.91.00000.0684 Positive64386.89813.2150.0150.0 Missing9131722924EGFR-CK5/6 status^d^\<0.0001 Negative3,31793.82186.2 Positive54167.625932.4 Missing1,182235p53 status^e^0.0572 Negative17290.1199.91745.92054.10.02110.8116 Positive5780.31419.7314.31885.7 Missing596893514Adjuvant chemotherapy\<0.0001 No2,59389.928210.1 Yes1,58583.232016.8 Missing862100Adjuvant hormonal therapy\<0.0001 No2,05982.543817.5 Yes2,56292.62047.4 Missing41970Distribution of the clinical variables in breast cancer patients according to the ANXA1 expression in all invasive tumors from the BCAC and BRCA1\|2 set of patients*ANXA1* annexin A1, *BCAC* Breast Cancer Association Consortium, *EGFR* epidermal growth factor receptor^a^ *P* value of the comparison between ANXA1 positive and negative patients in the BCAC set^b^ *P* value of the comparison between ANXA1 positive and negative patients in the BRCA1\|2 mutated set^c^ *P* value of the comparison between the two sets of ANXA1 positive patients: BCAC and BRCA1\|2 mutated patients^d^EGFR-CK5/6 status was defined as positive when CK5/6 and/or EGFR were positive^e^in the BCAC set, p53 status information was only available for the ABCS study

ANXA1 expression in breast cancer patients {#Sec7}
------------------------------------------

The distribution of patients and tumor characteristics of BCAC and *BRCA1/2* mutated patients is shown in Table [1](#Tab1){ref-type="table"}. Younger patients (\<50 years old) had slightly more often ANXA1 positive tumors compared with the older group (≥50 years old), in both subsets of patients. Poorly differentiated (high grade) tumors were associated with ANXA1 positive expression (tumor grade 2 or 3: OR~adj~ = 1.59; 95 % CI = 1.04--2.43); as well as those positive for basal-like markers (EGFR and/or CK5/6 positive) or triple negative (OR~adj~ = 4.21; 95 % CI = 3.22--5.50 and OR~adj~ = 6.01; 95 % CI = 4.61--8.01, respectively) (Additional file [6](#MOESM6){ref-type="media"}: Table S3).

ANXA1 expression was higher in the tumors from *BRCA1/2* mutated patients compared to BCAC patients overall: 48.6 % versus 12.4 %, respectively; *P* \<0.0001, and within specific breast cancer subtypes (Fig. [1](#Fig1){ref-type="fig"}). Although all *BRCA1/2* mutated carriers were only from Finland, the proportion of ANXA1 positives in the Finnish BCAC study (HEBCS) was the same compared to that of other BCAC studies (Additional file [1](#MOESM1){ref-type="media"}: Table S1A). Triple negative tumors in *BRCA1/2* mutated carriers showed a higher ANXA1 expression than triple negative breast cancer patients in the BCAC cohort (84.2 % versus 41.9 %, respectively; *P* \<0.0001). Also, there was a trend for higher ANXA1 expression with a decrease in hormone receptor positivity (i.e. subtypes ranging from luminal to HER2+ to triple negative; P~trend~ \<0.0001) (Fig. [1](#Fig1){ref-type="fig"}). Moreover, the *BRCA1* patients presented a slightly higher expression of ANXA1 compared with *BRCA2* mutated patients (57.6 % versus 37.5 %, respectively; *P* = 0.0583) (Table [1](#Tab1){ref-type="table"}). In *BRCA1/2* mutated patients, ANXA1 expression was associated with p53 positive status (OR~adj~ = 14.97; 95 % CI = 1.38--163.49; Additional file [6](#MOESM6){ref-type="media"}: Table S3).

Survival analysis according to ANXA1 expression {#Sec8}
-----------------------------------------------

We performed survival analysis of all BCAC patients with follow-up information (follow-up mean: 8.9 years). Patients with ANXA1 positive tumors showed a worse survival than the ANXA1 negative ones, both for OS (Fig. [2a](#Fig2){ref-type="fig"}; *P* = 0.0004) and BCSS (Additional file [7](#MOESM7){ref-type="media"}: Figure S4A; *P* \<0.0001). Similar trends of worse survival were seen in the nine separate cohorts, except for MCBCS (data not shown). After adjustment for clinical variables, a significant association between ANXA1 positivity and worse survival was observed only during the first 5 years of follow-up, but not after 10 years of follow-up (5-years BCSS: HR~adj~ = 1.35; 95 % CI = 1.05--1.73 and 10-years BCSS: HR~adj~ = 1.13; 95 % CI = 0.91--1.40; see also Additional file [8](#MOESM8){ref-type="media"}: Table S4). The strong association of ANXA1 expression with poorly differentiated grades and triple negative status likely contributed to this lack of association after 5 years. Similar time-dependent differences in survival were observed in lymph node positive patients (Fig. [2d](#Fig2){ref-type="fig"} and Additional file [7](#MOESM7){ref-type="media"}: Figure S4D), but ANXA1 expression did not influence survival in lymph node negative patients (Fig. [2c](#Fig2){ref-type="fig"} and Additional file [7](#MOESM7){ref-type="media"}: Figure S4C).Fig. 2Survival analysis. Survival curves, crude hazard ratios (HR) and adjusted hazard ratios (HR~adj~) in patients from BCAC according to ANXA1 expression for overall survival in (**a**) all BCAC patients, (**b**) HER2 positive patients, (**c**) lymph node negative patients and (**d**) lymph node positive patients. Hazard ratios were adjusted for: age of diagnosis; tumor grade; tumor size; lymph node metastasis; ER/PR status; and HER2 status. ANXA1: Annexin A1; BCAC: Breast Cancer Association Consortium; HR: Hazard ratio

Evaluating the tumor subtypes, ANXA1 high expression was specifically associated with an increased mortality in HER2 positive patients (10-years OS: HR~adj~ = 1.60; 95 % CI = 1.06--2.41 and 10-years BCSS: HR~adj~ = 1.70; 95 % CI = 1.17--2.45; Fig. [2b](#Fig2){ref-type="fig"} and Additional file [7](#MOESM7){ref-type="media"}: Figure S4B). The *P* values for interaction between ANXA1 and HER2 in a full model for BCSS or OS, including HER2 positive and negative cases, were 0.136 and 0.140, respectively. In addition, ANXA1 positive cases showed a slightly worse survival in the subgroup of patients older than 49 years old, which seemed to be related to menopausal status (data not shown). For none of the subgroup analyses the DMFS was significantly different between ANXA1 high and low expression groups.

ANXA1 expression and treatment response {#Sec9}
---------------------------------------

In order to explore the value of the ANXA1 expression in therapy resistance, we performed survival analyses in the group of patients who received adjuvant chemotherapy, as currently recommended. Using clinical guidelines \[[@CR32]\], the BCAC patients were classified according to the risk of recurrence using classic prognostic factors for determining the chance of distant metastases occurrence. Within the group that received adjuvant chemotherapy, patients with high risk of recurrence (HER2+ and/or pN+) showed a slightly worse OS and BCSS when ANXA1 was positive, compared with the ANXA1 negative ones in the group aged 50--69 years only (BCSS HR~adj~ = 2.02; 95 % CI = 1.21--3.36 and HR~adj~ = 1.41; 95 % CI = 0.80--2.50; Additional file [9](#MOESM9){ref-type="media"}: Figure S5).

Part of these patients (24.2 %) received anthracycline-based adjuvant chemotherapy. In the same high risk group aged 50--69 years, the ANXA1 positive cases presented a suggestive worse outcome after anthracycline-based adjuvant chemotherapy (10-years OS: HR~adj~ = 2.48; 95 % CI = 0.82--7.50; Fig. [3](#Fig3){ref-type="fig"} and BCSS: HR~adj~ = 2.96; 95 % CI = 0.92--9.57; Additional file [7](#MOESM7){ref-type="media"}: Figure S4F).Fig. 3Adjuvant treatment response. Survival curves, crude hazard ratios (HR) and adjusted hazard ratios (HR~adj~) according to ANXA1 expression in patients from BCAC with high risk of recurrence (HER2+ and/or pN+) who received anthracycline-based adjuvant chemotherapy. Overall survival and disease-free survival in (**a**, **b**) patients under 50 years old and (**c**, **d**) patients over 49 and under 70 years old. Hazard ratios were adjusted for: age of diagnosis; tumor grade; tumor size; lymph node metastasis; ER/PR status; and HER2 status. Note: low risk of recurrence was defined as: 35 years old or older; lymph node negative; tumor size ≥2 cm with any grade or tumor size ≥1 cm with tumor grade ≥2; high risk of recurrence was defined as: HER2+ and/or lymph node positive. ANXA1: Annexin A1; BCAC: Breast Cancer Association Consortium; HR: Hazard ratio

Discussion {#Sec10}
==========

Here, for the first time, the ANXA1 expression in a subset of *BRCA1/2* mutated carriers is described. We found a significantly higher expression of ANXA1 in tumors from familial breast cancer patients with *BRCA1/2* mutations compared with hospital and population-based breast cancer series.

We also found a higher ANXA1 expression in triple negative patients, confirming previous studies \[[@CR20], [@CR24], [@CR25]\]; association with poor differentiation grade is also described in other types of cancers \[[@CR33], [@CR34]\]. The association between ANXA1 expression and basal markers (EGFR-CK5/6) as shown in this study was also described in our previous work using a smaller cohort of breast cancer patients \[[@CR24]\], suggesting that ANXA1 may play a role in EGFR trafficking \[[@CR8], [@CR35]\]. Moreover, the higher frequency of ANXA1 expression in younger patients is not surprising since this group develops more often tumors of poor differentiation grade, triple negative status or with basal marker overexpression \[[@CR36]\].

The *BRCA1/2* mutated patients belong to a group that already contains a high number of triple negative and basal-like breast cancers \[[@CR37]\], but here we showed that triple negative tumors in *BRCA1/2* mutated carriers are even more highly expressing ANXA1 than triple negative patients in the BCAC cohort (Fig. [1](#Fig1){ref-type="fig"}). Perhaps such differences may involve the p53 expression, which was higher in the ANXA1 positive tumors (Additional file [6](#MOESM6){ref-type="media"}: Table S3). The tumor suppressor gene *TP53* is more commonly altered in *BRCA1/2*-related breast cancers, as measured either by IHC or mutation analysis \[[@CR38]\]. Indeed, *in vitro* studies in colon cancer cells suggest the existence of a binding site for p53 in the promoter of the *ANXA1* gene, inducing its expression and phosphorylation \[[@CR39], [@CR40]\]. Unfortunately, the group of *BRCA1/2* mutated carriers presented here is small, indicating that other studies focused in the ANXA1 expression profile in this group of patients are required.

In the survival analysis, ANXA1 positive tumors were independently associated with OS and BCSS in the first 5 years, but not in years 5 to 10. Findings of OS and BCSS were in line, signaling that a significant proportion of the patients with breast cancer died from it and not from other causes, which is expected especially since this series included a large proportion of relatively young breast cancer patients (Additional file [7](#MOESM7){ref-type="media"}: Figure S4). We had observed some indication for time dependency of ANXA1. Including ANXA1 time dependency in the model, we even found a suggestion of better survival in the ANXA1 positive group in the 5- to 10-year period of follow-up (BCSS: HR~adj~ = 0.65; 95 % CI = 0.40--1.03). For ANXA1 gene expression, using KM plotter \[[@CR41]\], a similar trend was seen with a worse recurrence-free survival in the first 5 years (HR = 1.15; CI = 1.18--10.29; *P* = 0.03), but not over the whole 10-year period (HR = 1.08; CI = 0.96--1.21; *P* = 0.21).

In our data, specifically patients with HER2+ tumors and ANXA1, overexpression showed a worse outcome, even after 5 years (10-years BCSS: HR~adj~ = 1.70; 95 % CI = 1.17--2.45). This is in line with the finding from Yom et al., who observed a worse recurrence-free survival for ANXA1 positive cases also in lymph node positive and HER2+ patients \[[@CR25]\]. Of note, most of the cases in our study were not treated with trastuzumab due to the period that they were diagnosed. Accordingly, the absolute OS was lower than would be expected after breast cancer treatment nowadays. Even so, the worse relative survival seen in our study is still relevant for HER2+ patients though with some caution because in most countries nowadays HER2+ patients are also treated with trastuzumab. Further research is therefore warranted to investigate the potential of ANXA1 as a predictor of trastuzumab resistance.

Of note, we observed some heterogeneity between the BCAC studies for the percentage of annexin A1 positive tumors (Additional file [1](#MOESM1){ref-type="media"}: Table S1A). These did not seem to be fully explained by differences in tumor characteristics (data not shown) and since the staining was done centrally there might have been some influence of the age of the tumor material and/or fixation at the time of embedding.

We also observed that ANXA1 overexpression was associated with worse survival in patients with high risk of recurrence in an age-dependent manner, with worst outcome in premenopausal patients, especially in the group that received anthracycline-based adjuvant chemotherapy. Unfortunately, for many cases, information about the type of chemotherapy was missing. Therefore, this might be due to chance and hypothesizing a mechanism for these findings is difficult. However, Ang et al. suggested that ANXA1 can regulate growth arrest induced by high levels of estrogen \[[@CR42]\], which is the typical physiological condition in premenopausal women. To our knowledge there are no other studies that evaluated ANXA1 expression and anthracycline-based chemotherapy resistance. ANXA1 overexpression was associated with cisplatin resistance in lung adenocarcinoma \[[@CR43]\], radiotherapy and chemotherapy resistance in nasopharyngeal carcinoma \[[@CR44]\], worse chemotherapy response after treatment with docetaxel, cisplatin and 5-fluorouracil in oral squamous cell carcinoma \[[@CR34]\], and poor response after neoadjuvant treatment with taxotere and carboplatin in triple negative breast cancer \[[@CR45]\].

Although ANXA1 has been described to play a role in metastasis formation in breast cancer \[[@CR46]\], the exact mechanism remains unknown. ANXA1 being also expressed in normal myoepithelial cells, the loss of ANXA1 expression in breast carcinomas has been described as a stage of malignant transformation \[[@CR19], [@CR20], [@CR47]\]. In breast cancer models, ANXA1 has been shown to modulate cell adhesion and motility \[[@CR23]\] by TGFβ-mediated EMT-like switch \[[@CR24]\] and by matrix metalloproteinase-9 regulation via NF-κB \[[@CR21], [@CR48]\], but another study found conflicting evidence \[[@CR49]\]. Moreover, as a glucocorticoid-induced protein, ANXA1 might also be able to provide critical interference in the tumor stroma and its microenvironment cross-talk \[[@CR17]\]. Altogether, our findings stress the importance of ANXA1 for prognosis and possibly for therapy resistance in breast cancer. We are also the first to show that there is a link between *BRCA1/2* mutations and ANXA1 overexpression.

Conclusion {#Sec11}
==========

We conclude here that ANXA1 expression is associated with tumors with selected well-known poor prognosis characteristics (e.g. poor differentiation grade, triple negative, *BRCA1/2* mutations). Our survival analysis showed that ANXA1 expression in breast tumors might be a biomarker candidate for breast cancer outcome prediction in high risk groups such as HER2+ cases, playing a complex role in chemotherapy resistance. Further studies are needed to elucidate whether ANXA1 is indeed a prognostic factor or may be used to predict chemotherapy response.
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Additional file 1: Table S1.Description of the studies involved in the BCAC, the percentage of tumors with ANXA1 expression and the list of ethics committees that approved the studies.Additional file 2: Figure S1.Immunohistochemistry for annexin A1 (ANXA1) expression in breast tumors.Additional file 3: Figure S2.ANXA1 scoring profile.Additional file 4: Table S2.Comparison of the clinical variables of breast cancer patients in the TMA versus those with ANXA1 scores for the BCAC and BRCA1\|2 patient series.Additional file 5: Figure S3.Flowchart showing the criteria used for the selection of patients in each analysis.Additional file 6: Table S3.Evaluation of the association between the ANXA1 expression and clinical variables in invasive tumors of BCAC and BRCA1\|2 breast cancer patients.Additional file 7: Figure S4.Survival curves, crude hazard ratios (HR) and adjusted hazard ratios (HR~adj~) in patients from BCAC according to ANXA1 expression.Additional file 8: Table S4.Cox proportional regression hazard models according the ANXA1 expression in all invasive breast cancers from the BCAC.Additional file 9: Figure S5.Survival curves, crude hazard ratios (HR) and adjusted (HR~adj~) according to ANXA1 expression in patients eligible for adjuvant chemotherapy in the BCAC.
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